Feature | Vendor Neutral Archive (VNA) | January 31, 2020 | By Melinda Taschetta-Millane

The Role of AI in VNA’s Growth

This feature originally ran as an introduction to the Vendor Neutral Archives (VNA) comparison chart in the January/February 2020 issue. You can view the chart here.

GE Centricity Pacs

Photo courtesy of GE Healthcare

The vendor neutral archive (VNA) market continues to grow, as does the amount of patient data being collected. However, today’s VNAs go beyond simply storing and distributing images. 

According to Market Reports World,[1] the global VNA and picture archive and communications system (PACS) market was estimated at $3.28 billion in 2017. The market is expected to register a compound annual growth rate (CAGR) of 5.9 percent during the forecast period — 2018 to 2023. North America accounted for the largest market share, making up approximately 60 percent of the global market share in 2017, while the Europe region was estimated to register the fastest CAGR through the forecast period of 2018-2023.

The demand for image archiving is rising, but PACS appears to still dominate over VNA, generating most of the revenue from the PACS replacements, according to the report. PACS systems are defined as storing data per the DICOM standard to maintain uniformity, and this internal format for storing data varies from company to company. However, VNA helps in centralized storage and the universalization of the image format. This need continues to grow, making the VNA market one of the fastest growing areas in information technology.

ResearchAndMarkets.com[2] reports that the factors driving the market growth include the increasing demand for the universalization of medical image archiving, reducing data storage costs, high-level integration with the electronic health records (EHR) industry and compatibility of VNA with older data archival systems.

“In today’s healthcare systems, information-based decision making is crucial for delivering quality care and maintaining efficiency in health management,” the report states. “Patient data must be available for effective decision-making. Though the information exists in various systems across numerous healthcare providers, it is not readily available to the clinicians. Hence, the integration of VNA or PACS with the EHR systems is crucial for the clinicians in effective decision-making. With the absence of VNA, large volumes of enterprise patient content are floating around in departmental silos, file systems which would ultimately lead to care decision made with incomplete information.”

The EHR trend began long ago, its growth accelerated by various government initiatives and programs across developed and developing nations. This adoption continues to grow globally, which helps to make content more readily available to clinicians. The report states that the benefits associated with the platform are driving the market.

AI’s Role in VNA

As with most things, AI is playing a role in the future and growth of the VNA market. At the 2019 Radiological Society of North America’s (RSNA) annual meeting, it was apparent from the vastly expanded AI Showcase that AI is a force to reckon with. It is a central point for all the technology to funnel through that facilities are already working with, giving the them one central point to have an HL7 interface to provide a framework for working through a VNA.

There is a convergence of these technologies coming together. ITN Editorial Contributor Greg Freiherr used the following analogy to describe this merger: “They are like snowballs rolling down a hill, gathering momentum while also gathering substance. And, they also are converging,” he said. “They are helping to solve real-world problems.”

For example, GE is taking a very broad strategy to this approach; the company is looking at Centricity PACS, which is its own system, and they are building an open AI orchestrator to run in the background. The idea is to bring in algorithms that are not necessarily their own. GE’s goal is to have more than a dozen next year, which they can integrate and use an orchestrator to keep it running in the background. Although for now this is designed for the PACS, GE says eventually they will broaden this into other PACS and VNAs as well, moving into specific hubs, linking to different machines. This will allow the focus to be specifically on the algorithms that are necessary to run off those machines, without being focused on the machine itself.

 

References:

1. Market Reports World, Global Vendor Neutral Archive (VNA) & PACS Market - Segmented by Application, Delivery Mode, Usage Model, Player type and Geography - Growth, Trend and Forecast (2018 - 2023), www.marketreportsworld.com/global-vendor-neutral-archive-vna-pacs-market-12343552. Accessed Jan. 13, 2020.

2. ResearchAndMarkets.com, Vendor Neutral Archive (VNA) and PACS - Market Analysis, Trends, and Forecasts, https://www.researchandmarkets.com/reports/4806437/vendor-neutral-archive-vna-and-pacs-market#pos-1. Accessed Jan. 13, 2020.

 

Related content:

Vendor Neutral Archives (VNA) Comparison Chart

Related Content

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 A brief article from Henry Ford Health System in Detroit, published today in Radiology, reports on the first presumptive case of COVID-19–associated acute necrotizing hemorrhagic encephalopathy.

A, Image from noncontrast head CT demonstrates symmetric hypoattenuation within the bilateral medial thalami (arrows). B, Axial CT venogram demonstrates patency of the cerebral venous vasculature, including the internal cerebral veins (arrows). C, Coronal reformat of aCT angiogram demonstrates normal appearance of the basilar artery and proximal posterior cerebral arteries. Image courtesy of the Radiological Society of North America (RSNA)

News | Coronavirus (COVID-19) | March 31, 2020
March 31, 2020 — A brief article fr
RSNA's open data repository will compile images and correlative data to create a comprehensive source for COVID-19 research and education efforts #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Coronavirus (COVID-19) | March 30, 2020
March 30, 2020 — The medical imaging community around the world is uniting to help address the...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Typical CT imaging features for COVID-19. Unenhanced, thin-section axial images of the lungs in a 52-year-old man with a positive RT-PCR (A-D) show bilateral, multifocal rounded (asterisks) and peripheral GGO (arrows) with superimposed interlobular septal thickening and visible intralobular lines (“crazy-paving”). Routine screening CT for diagnosis or exclusion of COVID-19 is currently not recommended by most professional organizations or the US Centers for Disease Control and Prevention. Image courtesy of RSNA

News | Coronavirus (COVID-19) | March 26, 2020
March 26, 2020 — The Radiological Society of North America (RSNA
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Representative examples of the attention heatmaps generated using Grad-CAM method for (a) COVID-19, (b) CAP, and (c) Non-Pneumonia. The heatmaps are standard Jet colormap and overlapped on the original image, the red color highlights the activation region associated with the predicted class. COVID-19 = coronavirus disease 2019, CAP = community acquired pneumonia. Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | March 20, 2020
March 20, 2020 — An arti...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Series CT scans in 35-year-old woman with COVID-19 pneumonia. (a) Scan obtained on illness days 1 showed multiple pure ground-glass opacity (GGO) mainly in right lower lobe. (b) Scan obtained on illness days 5 showed increased extent of GGO and early consolidation. (c) Scan obtained on illness days 11 showed multiple consolidation with almost the same extent. (d) Scan obtained on illness days 15 showed a mixed pattern with a slightly smaller extent, and the perilobular consolidation might suggest the presence of organizing pneumonia. The patient was discharged on illness days 17. Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | March 20, 2020
March 20, 2020 — In a new study pub
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SBI20

Image courtesy of Getty Images

News | Coronavirus (COVID-19) | March 17, 2020
March 17, 2020 — The journal Radiology ...
The low-dose chest computed tomography (CT) scans used in lung cancer screening do not appear to damage human DNA

Immunofluorescent staining performed to depict γ-H2AX foci. Representative images of γ-H2AX foci in peripheral blood lymphocytes in an 82-year-old woman who underwent standard-dose CT. (a) Nuclear DNA of four lymphocytes. (b) γ-H2AX foci (arrows). (c) Markers of DNA double-strand breaks. In this merged image, DNA is blue and γ-H2AX foci are red (arrows show small foci). γ-H2AX, a marker of DNA double-strand breaks, is a phosphorylated type of histone H2AX. Scale bar: 5 mm. Image courtesy of the Radiological Society of North America

News | Lung Cancer | March 11, 2020
March 11, 2020 — The low-dose chest computed tomog...